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OBJECTIVES: Develop and validate an epidemiological model to estimate the burden 
of post-menopausal osteoporosis (PMO) in terms of prevalence (women with low bone 
mineral density: BMD and/or a history of fracture), fracture incidence and attributable 
mortality up to 2020. METHODS: For validation purposes, the model was developed 
for Sweden (where the epidemiology of osteoporosis is well documented) and provided 
estimates from 1990. For each year of the study period, the “incident cohort”, deﬁned 
as women experiencing a ﬁrst osteoporotic fracture, was identiﬁed and run through 
a Markov model of 1-year cycles until 2020. Health states were based on the number 
of fractures (1, 2, 3) and death. Fracture by site was tracked for each health state 
(hip, vertebral, non-hip non vertebral). Transition probabilities reﬂected site-speciﬁc 
risk of death and subsequent fractures. BMD was included as a model output and 
reﬂected difference between women with and without a history of fracture. Model 
inputs included census from 1970 to 2020, incidence of fracture, relative risk of sub-
sequent fractures based on prior fracture, relative risk of death following a fracture 
by site, mean and standard deviation BMD by age. RESULTS: Model predictions 
averaged across age groups estimated the incidence of hip, vertebral and other osteo-
porotic fractures within a 5% margin of error compared to published data. Between 
2010 and 2020, the number of women aged 50 years is expected to increase by 9% 
whereas the number of osteoporotic fractures and women suffering from PMO (T-
score  2.5 or history of fracture) is expected to increase by 11% and 12% respec-
tively. CONCLUSIONS: A PMO disease model was developed and validated against 
Swedish data. This model can be adapted to other countries to assess the burden of 
illness and used to estimate the budgetary impact of therapies that reduce bone loss.
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MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT ON PAIN ON A 
DAILY BASIS
Dreiser RL1, Taieb C2
1Rheumatologist, Paris, France, 2PFSA, Boulogne, France
OBJECTIVES: To observe, under actual conditions of use, the effect obtained, in the 
context of management of knee osteoarthritis, combining a prescription of Avian ACS 
(1 g/day) between 2 courses of treatment of 3 injections of hyaluronic acid spaced out 
by a maximum of 12 months. METHODS: Pragmatic, longitudinal and prospective 
follow-up carried out by rheumatologists in the context of their daily professional 
activities RESULTS: The results presented come from a preliminary analysis concern-
ing the ﬁrst patients assessable at 6 months. Forty-ﬁve percent of the patients are 
treated with hyaluronic acid for left knee osteoarthritis and 52% are treated with 
hyaluronic acid for right knee osteoarthritis (3% treated for both). Average pain 
during activities of daily living was measured by means of a visual analogue scale. It 
is 53.28 o 20.83 at inclusion. At 18 weeks, this same average pain measured under 
the same conditions is 37.96 o 17.17. A third measurement at 24 weeks situates it at 
35.62 o 17.95. Pain during activities of daily living is signiﬁcantly reduced between 
inclusion and week 18 (p  0.0056). The average reduction in pain during activities 
of daily living measured between inclusion and 6 months is also signiﬁcant (p  0.001). 
Accordingly, the reduction obtained in 6 months is 33%. CONCLUSIONS: Our 
study, which assesses the effect on pain obtained in the context of management of 
subjects with knee osteoarthritis, combining a prescription of Structum® (1 g/day) 
between two courses of treatment of three injections of Structovial®, showed a reduc-
tion in pain during activities of daily living. This reduction in pain, which is signiﬁcant 
at 18 weeks, then perpetuated at 6 months, shows the relevance of the treatment 
protocol used by the doctors.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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VERTEPORFIN IN NEOVASCULAR AMD: REAL LIFE CONFIRMS 
CLINICAL TRIALS RESULTS
Sambuc R1, Le Pen C2, Soubrane G3, Quentel G4, Zerouta S5, Ponthieux A5
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OBJECTIVES: Verteporﬁn is the ﬁrst product approved for neovascular age-related 
macular degeneration (AMD). The severity of AMD, the innovative aspect of Verte-
porﬁn and its ﬁnancial implications motivated French Authorities to request a real life 
drug utilization study. To describe in France patients treated by Verteporﬁn for neo-
vascular AMD, their visual acuity changes (responders: VA loss 15 letters) and 
number of needed treatments. METHODS: Observational, prospective, multi-center 
study with two parts: a registry for all patients treated by Verteporﬁn for AMD or 
other diseases; a cohort with two years follow-up of neovascular AMD patients treated 
by Verteporﬁn. RESULTS: In the registry, 96.8% of patients were treated by Verte-
porﬁn in its approved indication.Iin the cohort, from May 2004 to December 2006, 
438 patients were included (39 ophthalmologists). Population was 78.3 o 7.6 years, 
67.6% women. At baseline, 58.2% of patients had bilateral AMD. Diagnosis was 
done 9.0 months ago. In the study eye, lesion type was predominately classic in 270 
patients (61.6%) and occult in 168 patients (38.4%); 35.5% of patients were previ-
ously treated by Verteporﬁn. A total of 65.5% of population was retreated by Verte-
porﬁn during the follow-up, the ﬁrst retreatment was at 4.3 months from baseline; 
average number of treatments was 2.21 (predominately classic: 2.50; occult: 0.80). 
Comparing to year 1, proportion of patients treated by Verteporﬁn decreased in the 
second year: 64.4% vs 11.5%. At two years, responder rates were 67.8% in whole 
naïve population, 67.2% and 68.2% for predominately classic and occult respectively. 
In average, visual acuity change was 7 letters (from 43 to 36 letters). No unexpected 
adverse event was observed. CONCLUSIONS: This study conﬁrms the efﬁcacy of 
Verteporﬁn in real life setting but treatment rate was lower than in pivotal studies.
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COMPARISON OF OUTCOMES FOR MULTIFOCAL INTRA-OCULAR 
LENSES (MIOLS): A META-ANALYSIS
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OBJECTIVES: To compare the clinical outcomes of different MIOLs using a meta-
analysis based on the available information reported in the international literature. 
METHODS: All comparative clinical trials including at least one MIOL were extracted 
from the literature. Patients had to have surgery for either cataract or presbyopia. 
Clinical outcomes included uncorrected near and distance visual acuity (UNVA, 
UDVA in LogMAR), spectacle independence and halos. Random effects meta-analyses 
were conducted to compare outcomes for different types of implants. RESULTS: 
Twenty papers were identiﬁed with 11 monofocal IOLs and 35 MIOLs (19 diffractives 
including 12 ReSTORs, 14 refractives and 2 accommodatives). In comparison to 
monofocal IOLs, MIOLs had better UDVA (0.165 vs. 0.093, p  0.001) and better 
UNVA (0.47 vs. 0.14, p  0.0001) resulting in a higher spectacle independence inci-
dence rate (IRR  3.62, P  0.0001). In comparison to refractive MIOLs, diffractive 
MIOLs had similar UDVA (0.105 vs. 0.085, p  0.78), and better UNVA (0.22 vs. 
0.082, p  0.0001) resulting in a higher spectacle independence incidence rate (IRR  
1.75, P  0.001). In comparison to other MIOLs, ReSTOR had better UDVA (0.067 
vs. 0.109, p  0.0001), and better UNVA (0.064 vs. 0.184, p  0.006) resulting in a 
higher spectacle independence incidence rate (IRR  2.04, P  0.004). We found no 
statistically signiﬁcant differences in halo incidence rates for different types of implants. 
CONCLUSIONS: MIOLs provide better UNVA and UDVA than monofocal IOLs, 
which lessens the need for spectacles. The design of the MIOL might play a role in 
post-surgical outcomes of different models. ReSTOR, a diffractive MIOL, showed 
better UNVA, UDVA and higher rates of spectacle independence than the other 
MIOLs.
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TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGAN-
GANFORT AND TRAVATAN-DUOTRAV: AN ANALYSIS CONDUCTED 
ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH 
DATABASE
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OBJECTIVES: The objective of this analysis was to compare treatment persistency of 
three treatment sequences: Xalatan-Xalacom (XX), Lumigan-Ganfort (LG) and Trav-
atan-DuoTrav (TD) according to data collected in the United-Kingdom General Prac-
titioner Research Database (UK-GPRD). METHODS: Patients with a diagnosis of 
ocular hypertension or glaucoma, or treated with a topical treatment, surgery or laser 
were selected. Patients with sequence prescription of XX, LG and TD were selected. 
A treatment failure was deﬁned as a prescription change (adding or removing a topical 
treatment). Time to treatment failure was compared using Wilcoxon test applied to 
survival curves. Adjustment on confounding variables was performed with the pro-
pensity score method using a logistic stepwise regression. RESULTS: 1562 patients 
were treated by XX, 110 by LG and 114 by TD. Mean age was 75 years and the sex-
ratio was close to 1 male/ 1 female. No demographic or co-morbidity differences 
between treatment sequences were observed. At 30 months, 66.5% of the XX patients 
had not failed (remain with the same treatment sequence), versus 60.5% of the LG 
and 75.1% of the TD patients (Wilcoxon, P  0.005). At 60 months these results 
became, 42.2%, 49.9%, and 52.0%, respectively (Wilcoxon, P  0.04). Adjustment 
for confounding variables did not change these estimates. CONCLUSIONS: Accord-
ing to the UK-GPRD information, the Travatan-DuoTrav treatment sequence was 
associated with longer treatment persistence
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SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 
5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES
Walczak J, Nogas G, Chmiel M, Kowalska M
Arcana Institute, Cracow, Poland
OBJECTIVES: The aim of the review was to evaluate the efﬁcacy and safety of 
imiquimod 5% cream compared with vehicle for the treatment of actinic keratoses. 
METHODS: The analysis was performed in accordance with the rules of systematic 
review, based on the Cochrane Collaboration (Cochrane Reviewer’s Handbook) 
guidelines and the Health Technology Assessment Agency in Poland (AOTM) recom-
mendations. RESULTS: Imiquimod 5 percent cream versus vehicle in short time 
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period: In the period of four as well as eigth – weeks course of treatment with imiqui-
mod 5% cream, therapy resulted in signiﬁcantly higher chance of achieving complete 
clearance. Patients treated with imiquimod more frequently achieved clearance level 
higher than 75% of baseline actinic keratoses compared with the subject in vehicle 
group. Adverse events were more frequently recorded within the group of subjects 
who received imiquimod in comparison with vehicle group. The chance of experienc-
ing local skin reaction such as erythema, ﬂaking/scaling/dryness, scabbing/crusting, 
oedema, vesicles, erosin/ulceration was signiﬁcantly higher in experimental group. 
Imiquimod ﬁve percent cream versus vehicle in long time period: Imiquimod 5% cream 
used 3 times a week for 24 weeks was an effective treatment for actinic keratosis 
measured by the probability of achieving complete clearance and partial clearance rate 
(more than 75% reduction in baseline lesions). Frequency of adverse events and local 
skin reactions was higher during the imiquimod treatment in comparison with 
placebo. Imiquimod ﬁve percent cream versus vehicle in patient with solid organ 
transplants: Treatment with imiquimod 5% cream for 24 weeks in kidney, heart and 
liver transplant patients resulted in signiﬁcantly higher probability of achieving com-
plete and partial clearance rates of actinic keratoses. There were no signiﬁcant differ-
ences in incidence of adverse events between groups. CONCLUSIONS: Imiquimod 
ﬁve percent cream appears to be effective and safe alternative therapy for the treatment 
of actinic keratoses.
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RESTOR® VERSUS ACRILISA® : ND-YAG LASER INCIDENCE RATE 
COMPARISON 18 MONTHS AFTER SURGERY
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OBJECTIVES: The aim of this study was to compare the 18 months Nd : Yag laser 
incidence rate of two multifocal intra-ocular lenses, ReSTOR® and Acrilisa®, implanted 
by a single surgeon following his usual practice. METHODS: This retrospective study 
was based on all patients implanted with a ReSTOR® or Acrilisa® multi-focal lens 
since Q3–2004 at one site. All patients with either cataract or clear lens were operated 
by the same surgeon. Medical data were obtained from patient charts. 18-months post 
surgical data were obtained from the surgeon’s medical ﬁles and from other ophthal-
mologists, if involved in post-surgical care. Time to Nd : Yag laser analysis was carried 
out using Kaplan-Meier survival curves. Imbalance on confounding variables was 
adjusted with a Cox model. RESULTS: Eighty patients (160 eyes) were bilaterally 
implanted with ReSTOR® and 76 (152 eyes) with Acrilisa®. Patients with ReSTOR® 
were more often male (52.5% versus 30.7%; P  0.01) and younger (63.1 versus 65.8; 
P  0.01). After one year of follow-up, 3.6% of the ReSTOR® eyes had Nd : Yag laser 
versus 6.8% of the Acrilisa® eyes. After 18 months, the incidence rates were 4.6% 
and 26.0%, respectively (P  0.0001). Age was weakly associated with Nd : Yag laser 
(p  0.09). Eyes with Acrilisa® had 5.62 [2.64–14.02; P  0.0002] more chances to 
have Nd : Yag laser than ReSTOR®. This persisted after adjusting on age [Hazard 
Ratio: 6.61; 2.61–16.76; P  0.0001]. CONCLUSIONS: This analysis conducted at 
18 months suggested that following usual surgical practice, ReSTOR® eyes had sig-
niﬁcantly less capsulotomy than those implanted with Acrilisa®. Young population 
were slightly more exposed at Nd : Yag laser. Analyses at two and three years will be 
required to conﬁrm these ﬁndings.
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CONJUNCTIVAL HYPERAEMIA ASSOCIATED WITH THE FIXED 
COMBINATIONS OF LATANOPROST/TIMOLOL AND BIMATOPROST/
TIMOLOL IN THE TREATMENT OF OCULAR HYPERTENSION OR 
GLAUCOMA
Vinuesa MJ1, Vinuesa I2, Díaz S3, Martin I3, Soto J3, Fernandez-Arias I3
1Salamanca University, Salamanca, Spain, 2Hospital Punta de Europa, Algeciras, Cádiz, Spain, 
3Pﬁzer, Madrid, Spain
OBJECTIVES: To assess the association of conjunctival hyperaemia with the ﬁxed 
combinations of latanoprost/timolol (LT/TM) and bimatoprost/timolol (BM/TM) in 
the treatment of ocular hypertension or glaucoma using a systematic review and meta-
analyisis of randomized clinical trials (RCTs). METHODS: A systematic search for 
RCTs published between 2000 and 2009 was conducted in Medline, Embase and 
Controlled Trials Register databases. The outcome measured was the appearance of 
conjunctival hyperaemia in studies comparing the use of either LT/TM or BM/TM 
versus different therapeutic options. Statistical analysis was performed including the 
calculation of odds ratio (OR) and its respective conﬁdence interval, along with the 
inter-trial statistical heterogeneity. A sensitivity analysis was also carried out. 
RESULTS: A total of 16 RCTs comparing LT/TM versus distinct therapeutic alterna-
tives and 5 CT comparing BM/TM versus different therapeutic options fulﬁlled criteria 
to be included in the meta-analysis. Although heterogeneity of both comparisons was 
not very high in both the LT/TM group (Q  24.47; p  0.057; I2  38.7 %) and 
the BM/TM group (Q  5.19; p  0.268; I2  22.94 %), the estimation of the OR by 
the random effects model was considered the most appropriate. According to this 
model the ﬁnal OR for the LT/TM group was 0.56 (IC95%: 0.37–0.83), p  0.05 and 
for the BT/TM group the OR was 0.94 (IC95%: 0.66–1.34), p  0.05. In the sensitivity 
analysis performed, none of the RCTs included in this meta-analysis had an important 
effect in the global estimation of OR. CONCLUSIONS: According to available data, 
the use of LT/TM is associated with a signiﬁcant reduction in the development of 
conjunctival hyperaemia versus the comparators used in the RCTs, whereas the use 
of BM/TM produces a conjunctival hyperaemia rate similar to its comparators.
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THE APPLICATION OF DISCRETE EVENT SIMULATION TO 
QUANTITATIVE RISK BENEFIT ANALYSIS
Maguire A1, Douglas I2, Blak BT3
1United BioSource Corporation, London, London, UK, 2London School of Hygiene and 
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OBJECTIVES: To date, quantitative risk beneﬁt has mainly involved the translation 
of Cost-Effectiveness techniques or utility adjusted epidemiological statistics. We aim 
to describe how Discrete Event Simulation “DES” offers the possibility of modelling 
the occurrence of several adverse events and beneﬁcial events simultaneously whilst 
accounting for competing events. METHODS: Firstly, a longitudinal patient database 
is used to identify the target patient population. Secondly, incidence rates for the out-
comes are calculated from the entire database, thereby providing the necessary granu-
larity in terms of the predictive factors for the outcomes. The annual probability for 
each outcome is then assigned to each patient in the cohort and DES generates time 
to each event. Thereby the expected events for an unexposed patient cohort is created 
to which relative risks are applied to model drug exposure. An example using glau-
coma patients is presented using data from The Health Improvement Network. 
RESULTS: We obtained data on 17,652 glaucoma patients who were known to be 
receiving glaucoma therapy at January 1, 2007. Patients were characterised according 
to the principal determinants of the outcomes (heart failure, asthma/COPD exacerba-
tion). The same database provided general population incidence rates for the outcomes 
which were assigned to each patient according to their characteristics. National sta-
tistics provided death rates. The expected events over one year for a cohort of 10,000 
glaucoma patients were: HF  95; asthma/COPD  143; deaths  605. CONCLU-
SIONS: These expected numbers represent the occurrence of events in the natural 
history cohort. They were obtained by summing the outcome probabilities across the 
patient group. They do, however, represent the ﬁrst step in creating a comprehensive 
method for risk-beneﬁt quantiﬁcation via DES and large patient databases; beneﬁt can 
be modelled if expressed as the occurrence of an event. The method will need to 
incorporate uncertainty in all the input parameters and to update the probabilities 
after an event has occurred.
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COSTS-OF-ILLNESS OF ULCUS CRURIS IN GERMANY: RESULTS OF 
TWO APPROACHES
Purwins S1, Augustin M1, Herberger K1, Debus S2, Rustenbach SJ1
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Germany
OBJECTIVES: Estimation of cost-of-illness (COI) of leg ulcers in two German cross-
sectional studies using different methodical approaches. METHODS: A direct and an 
indirect method for cost estimation were utilized. In a nationwide cross-sectional study 
in 33 specialized dermatological, surgical and general-medical wound centres, resource 
consumption and associated costs of venous leg ulcer(s) were collected directly from 
physicians and patients. In a second cross-sectional regional study, involving 147 
institutions (hospitals, residencies, nursing services, dermatological ofﬁces, services for 
homeless and addictives) treating patients with ulcus cruris, resource consumption and 
associated costs were inferred from history, wound condition and actual/previous 
treatments based on standardized cost categories. Main economic parameters in both 
studies were direct, indirect and intangible costs (health related quality of life, HRQoL) 
from the societal perspective. RESULTS: The national study enrolled n  218 patients 
with a mean age of 69.8 years (regional study: n  502, 71 years). Wounds existed 
for 7 (regional 9) years on average. The mean total COI per year and patient was 
a9,569 (a10,624). While direct costs summed up to a8658 (a9851), indirect costs were 
much lower a911 (a772). Of direct costs, a7631 (a9122) were covered by the Statutory 
Health Insurances (SHI) and a1027 (a730) by the patients. For SHI, major cost factors 
were inpatient costs, non-drug treatments and physicians/nurses fees. Moreover, clini-
cal predictors such as wound size, number and duration as well as wound etiology 
and characteristics of care (quality, support) were identiﬁed. All patients were severely 
impaired in their HRQoL, implying a high burden of disease and relevant intangible 
costs. CONCLUSIONS: Chronic leg ulcers generate highly relevant COI. Despite dif-
ferent recruitment and cost estimation methods, both studies resulted in comparable 
direct, indirect and intangible costs; observed differences can be attributed to sample 
characteristics. The results point to early and qualiﬁed disease management in all 
related health services areas.
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COSTS OF PATIENTS WITH OCCUPATIONAL SEVERE CHRONIC HAND 
ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROIDS FOR 
EMPLOYER’S MUTUAL INSURANCE COMPANIES IN SPAIN
Mascaro JM1, Querol I2, Lindner L3, Prior M3, Oliver J4, Halbach RP4
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OBJECTIVES: To estimate the direct and indirect costs of occupational severe chronic 
hand eczema (OSCHE) in patients refractory to topical corticosteroids from the per-
spective of employer’s mutual insurance companies (EMIC) in Spain. METHODS: An 
employer’s mutual insurance company in Spain usually covers 75% of salaries and 
100% of medical treatments of patients on occupational sick leave. A decision analytic 
